Centaurus Financial’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$881K Buy
6,319
+1,024
+19% +$143K 0.04% 377
2025
Q4
$650K Sell
5,295
-1,697
-24% -$206K 0.03% 444
2025
Q3
$776K Buy
6,992
+1,168
+20% +$133K 0.04% 398
2025
Q2
$646K Buy
5,824
+731
+14% +$77.8K 0.04% 399
2025
Q1
$571K Buy
5,093
+231
+5% +$23.8K 0.03% 419
2024
Q4
$449K Buy
4,862
+1,332
+38% +$120K 0.03% 469
2024
Q3
$296K Sell
3,530
-1,268
-26% -$96.8K 0.02% 540
2024
Q2
$329K Buy
4,798
+529
+12% +$35.3K 0.02% 474
2024
Q1
$313K Sell
4,269
-1,272
-23% -$97.8K 0.02% 491
2023
Q4
$449K Sell
5,541
-674
-11% -$52.4K 0.03% 388
2023
Q3
$466K Buy
6,215
+1,155
+23% +$88.8K 0.04% 369
2023
Q2
$390K Sell
5,060
-2,702
-35% -$215K 0.03% 409
2023
Q1
$644K Buy
7,762
+756
+11% +$62.6K 0.05% 331
2022
Q4
$601K Sell
7,006
-1,849
-21% -$146K 0.06% 322
2022
Q3
$546K Buy
8,855
+100
+1% +$6.31K 0.05% 335
2022
Q2
$541K Sell
8,755
-1,822
-17% -$113K 0.05% 354
2022
Q1
$629K Buy
10,577
+596
+6% +$38.1K 0.05% 370
2021
Q4
$725K Sell
9,981
-1,779
-15% -$123K 0.05% 341
2021
Q3
$821K Buy
11,760
+228
+2% +$16K 0.07% 310
2021
Q2
$794K Buy
11,532
+1,587
+16% +$106K 0.07% 322
2021
Q1
$643K Buy
9,945
+2,883
+41% +$186K 0.06% 313
2020
Q4
$411K Sell
7,062
-905
-11% -$54.6K 0.04% 405
2020
Q3
$503K Sell
7,967
-5,267
-40% -$365K 0.07% 274
2020
Q2
$1.02M Buy
13,234
+6,937
+110% +$532K 0.15% 170
2020
Q1
$471K Sell
6,297
-825
-12% -$57K 0.09% 216
2019
Q4
$463K Sell
7,122
-558
-7% -$36.3K 0.06% 321
2019
Q3
$487K Buy
7,680
+657
+9% +$42.9K 0.08% 272
2019
Q2
$474K Buy
7,023
+6,568
+1,444% +$432K 0.07% 277
2019
Q1
$7K Buy
455
+102
+29% +$6.78K 0.04% 313
2018
Q4
$6 Buy
353
+346
+4,943% +$24.2K 0.04% 259
2018
Q3
$507 Sell
7
-10,592
-100% -$800K 0.09% 242
2018
Q2
$751K Buy
10,599
+4,946
+87% +$349K 0.1% 206
2018
Q1
$426K Buy
5,653
+236
+4% +$18.8K 0.1% 220
2017
Q4
$388K Buy
+5,417
New +$411K 0.1% 213

Other funds holding GILD

Centaurus Financial's GILD Position: Q1 2026 in Review

Centaurus Financial increased its Gilead Sciences (GILD) stake by 19% in Q1 2026, buying an estimated $143K and bringing the position to 6,319 shares worth $881K. The position accounts for 0.04% of the portfolio, ranked #377.

Centaurus Financial first reported a position in GILD in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.02M in Q2 2020. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Centaurus Financial held 6,319 shares of Gilead Sciences worth $881K as of Q1 2026.
  • Centaurus Financial bought 1,024 Gilead Sciences shares in Q1 2026, an estimated $143K.
  • Gilead Sciences made up 0.04% of Centaurus Financial's portfolio in Q1 2026, its #377 holding.
  • Centaurus Financial first reported a position in Gilead Sciences in Q4 2017 and has held it in 34 quarters since.
  • Centaurus Financial's Gilead Sciences position peaked at $1.02M in Q2 2020.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Centaurus Financial's 13F filing for Q1 2026, filed 18 May 2026.